Distinct temporal trajectories and risk factors for Post-acute sequelae of SARS-CoV-2 infection.
COVID-19
PASC
SARS-CoV-2
long COVID
symptom clusters
Journal
Frontiers in medicine
ISSN: 2296-858X
Titre abrégé: Front Med (Lausanne)
Pays: Switzerland
ID NLM: 101648047
Informations de publication
Date de publication:
2023
2023
Historique:
received:
23
05
2023
accepted:
19
09
2023
medline:
1
11
2023
pubmed:
1
11
2023
entrez:
1
11
2023
Statut:
epublish
Résumé
The understanding of Post-acute sequelae of SARS-CoV-2 infection (PASC) can be improved by longitudinal assessment of symptoms encompassing the acute illness period. To gain insight into the various disease trajectories of PASC, we assessed symptom evolution and clinical factors associated with the development of PASC over 3 months, starting with the acute illness period. We conducted a prospective cohort study to identify parameters associated with PASC. We performed cluster and case control analyses of clinical data, including symptomatology collected over 3 months following infection. We identified three phenotypic clusters associated with PASC that could be characterized as remittent, persistent, or incident based on the 3-month change in symptom number compared to study entry: remittent (median; min, max: -4; -17, 3), persistent (-2; -14, 7), or incident (4.5; -5, 17) ( An incident disease phenotype characterized by symptoms that were absent during acute illness and the observed association with high dose steroids during acute illness have potential critical implications for preventing PASC.
Sections du résumé
Background
UNASSIGNED
The understanding of Post-acute sequelae of SARS-CoV-2 infection (PASC) can be improved by longitudinal assessment of symptoms encompassing the acute illness period. To gain insight into the various disease trajectories of PASC, we assessed symptom evolution and clinical factors associated with the development of PASC over 3 months, starting with the acute illness period.
Methods
UNASSIGNED
We conducted a prospective cohort study to identify parameters associated with PASC. We performed cluster and case control analyses of clinical data, including symptomatology collected over 3 months following infection.
Results
UNASSIGNED
We identified three phenotypic clusters associated with PASC that could be characterized as remittent, persistent, or incident based on the 3-month change in symptom number compared to study entry: remittent (median; min, max: -4; -17, 3), persistent (-2; -14, 7), or incident (4.5; -5, 17) (
Conclusion
UNASSIGNED
An incident disease phenotype characterized by symptoms that were absent during acute illness and the observed association with high dose steroids during acute illness have potential critical implications for preventing PASC.
Identifiants
pubmed: 37908849
doi: 10.3389/fmed.2023.1227883
pmc: PMC10614284
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1227883Informations de copyright
Copyright © 2023 Chen, Parthasarathy, Leung, Wu, Drake, Ridaura, Zisser, Conrad, Tapson, Moy, deFilippi, Rosas, Prabhakar, Basit, Salvatore, Krishnan and Kim.
Déclaration de conflit d'intérêts
CC, JL, MW, KD, and CK maintain equity ownership and employment at Verily Life Sciences. SP reports personal fees from Jazz Pharmaceuticals, Inc., and UpToDate, Inc., and grants from Philips, Inc., Sommetrics, Inc., and Regeneron. CRd serves on advisory boards for Abbott Diagnostics, Ortho/Quidel Diagnostics, and Roche Diagnostics. JK receives research funding from Regeneron. JK has also provided consulting for GlaxoSmithKline, AstraZeneca, CereVu Medical, Propeller/ResMed, and BData, Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The reviewer RP declared a past co-authorship with the author SP to the handling editor.
Références
Nat Commun. 2021 Nov 12;12(1):6571
pubmed: 34772922
JAMA Psychiatry. 2022 Aug 1;79(8):811-817
pubmed: 35767287
Cochrane Database Syst Rev. 2017 Nov 06;11:CD008727
pubmed: 29106702
PLoS One. 2022 Sep 29;17(9):e0275274
pubmed: 36174032
Open Forum Infect Dis. 2022 Mar 07;9(4):ofac060
pubmed: 35265728
Neurosci Insights. 2022 Jul 22;17:26331055221114817
pubmed: 35910083
N Engl J Med. 2020 Nov 5;383(19):1813-1826
pubmed: 32445440
Cell Rep. 2021 Aug 10;36(6):109518
pubmed: 34358460
Nat Med. 2021 Apr;27(4):601-615
pubmed: 33753937
Sci Transl Med. 2021 Jun 2;13(596):
pubmed: 33941622
N Engl J Med. 2021 Feb 25;384(8):693-704
pubmed: 32678530
Nat Med. 2023 Jan;29(1):226-235
pubmed: 36456834
Pathogens. 2022 Feb 19;11(2):
pubmed: 35215212
Trends Immunol. 2022 Apr;43(4):268-270
pubmed: 35272932
Lancet. 2022 Aug 6;400(10350):452-461
pubmed: 35934007
J Infect. 2022 Jul;85(1):57-63
pubmed: 35605805
Sci Adv. 2021 Mar 19;7(12):
pubmed: 33741586
JAMA Netw Open. 2021 May 3;4(5):e2111417
pubmed: 34037731
Am J Physiol. 1980 Jul;239(1):F30-43
pubmed: 7395993
JAMA Netw Open. 2021 Oct 1;4(10):e2128568
pubmed: 34643720
J Infect Dis. 2022 Nov 1;226(9):1593-1607
pubmed: 35429399
Cell. 2022 Mar 3;185(5):881-895.e20
pubmed: 35216672
Nature. 2023 Nov;623(7985):139-148
pubmed: 37748514
Clin Infect Dis. 2023 Jun 8;76(11):1930-1941
pubmed: 36705268
Nat Med. 2023 Sep;29(9):2347-2357
pubmed: 37605079
Science. 2022 Mar 11;375(6585):1122-1127
pubmed: 35271343